Free Trial

Artelo Biosciences (ARTL) Competitors

Artelo Biosciences logo
$7.20 +0.11 (+1.56%)
Closing price 06/13/2025 03:58 PM Eastern
Extended Trading
$6.85 -0.34 (-4.74%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARTL vs. GELS, VYNE, AIMD, SYBX, EDSA, ERNA, BLRX, IBIO, ALLR, and NXTC

Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Gelteq (GELS), VYNE Therapeutics (VYNE), Ainos (AIMD), Synlogic (SYBX), Edesa Biotech (EDSA), Eterna Therapeutics (ERNA), BioLineRx (BLRX), iBio (IBIO), Allarity Therapeutics (ALLR), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

Artelo Biosciences vs. Its Competitors

Artelo Biosciences (NASDAQ:ARTL) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.

Gelteq's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -104.59% -94.06%
Gelteq N/A N/A N/A

Artelo Biosciences currently has a consensus price target of $33.00, suggesting a potential upside of 358.65%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Gelteq.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.20
Gelteq
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Artelo Biosciences had 2 more articles in the media than Gelteq. MarketBeat recorded 7 mentions for Artelo Biosciences and 5 mentions for Gelteq. Gelteq's average media sentiment score of 0.94 beat Artelo Biosciences' score of -0.18 indicating that Gelteq is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artelo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gelteq
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

0.9% of Artelo Biosciences shares are owned by institutional investors. 0.8% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$9.29M-$2.99-2.41
GelteqN/AN/AN/AN/AN/A

Artelo Biosciences received 51 more outperform votes than Gelteq when rated by MarketBeat users.

CompanyUnderperformOutperform
Artelo BiosciencesOutperform Votes
51
77.27%
Underperform Votes
15
22.73%
GelteqN/AN/A

Summary

Artelo Biosciences beats Gelteq on 8 of the 11 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTL vs. The Competition

MetricArtelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$23.61M$6.88B$5.57B$8.51B
Dividend YieldN/A2.49%5.27%4.16%
P/E Ratio-2.518.4626.7519.65
Price / SalesN/A262.48404.17152.19
Price / CashN/A65.8538.2534.64
Price / Book1.756.526.964.59
Net Income-$9.29M$143.26M$3.23B$248.23M
7 Day Performance7.07%-0.21%-1.23%-1.07%
1 Month Performance27.57%10.62%6.34%2.59%
1 Year Performance-12.47%3.63%33.04%13.50%

Artelo Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTL
Artelo Biosciences
2.1022 of 5 stars
$7.20
+1.6%
$33.00
+358.7%
-12.5%$23.61MN/A-2.515News Coverage
Analyst Downgrade
Stock Split
Short Interest ↓
Gap Down
GELS
Gelteq
N/A$1.50
-6.3%
N/AN/A$14.16MN/A0.00N/APositive News
Gap Down
VYNE
VYNE Therapeutics
2.4775 of 5 stars
$0.93
-2.3%
$6.25
+573.5%
-60.9%$14.12M$605K-1.0830Short Interest ↑
High Trading Volume
AIMD
Ainos
1.1806 of 5 stars
$0.63
-6.5%
N/A-42.7%$14.02M$106.21K-0.4940Positive News
Gap Down
SYBX
Synlogic
1.2634 of 5 stars
$1.19
+3.7%
N/A-22.8%$13.94M$8K-0.2980Upcoming Earnings
Short Interest ↑
Gap Up
EDSA
Edesa Biotech
3.343 of 5 stars
$1.99
+1.5%
$21.00
+955.3%
-56.8%$13.76MN/A-1.0620Positive News
Short Interest ↓
ERNA
Eterna Therapeutics
0.9045 of 5 stars
$0.22
+0.5%
N/A-92.0%$13.66M$535K-0.0310Stock Split
Short Interest ↓
Gap Down
BLRX
BioLineRx
3.6109 of 5 stars
$4.10
-21.9%
$26.00
+534.1%
-82.4%$13.65M$22.34M-0.4740Positive News
Gap Down
High Trading Volume
IBIO
iBio
1.116 of 5 stars
$0.82
+6.6%
$4.30
+423.8%
-63.6%$13.56M$375K0.00100Gap Down
ALLR
Allarity Therapeutics
0.5337 of 5 stars
$0.89
+3.2%
N/A-94.1%$13.49MN/A0.0010News Coverage
NXTC
NextCure
4.6476 of 5 stars
$0.48
-2.5%
$3.50
+628.7%
-57.4%$13.47MN/A-0.2390Positive News
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:ARTL) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners